Enanta Pharmaceuticals Inc (ENTA) - Total Liabilities
Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has total liabilities worth $198.12 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Enanta Pharmaceuticals Inc (ENTA) equity growth momentum to track the company's year-over-year net asset growth rate.
Enanta Pharmaceuticals Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Enanta Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Enanta Pharmaceuticals Inc to measure how efficiently the company converts operating cash flow to free cash.
Enanta Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
STL Technology Co Ltd
TWO:4931
|
Taiwan | NT$868.38 Million |
|
Royal Group Co Ltd
SHE:002329
|
China | CN¥3.85 Billion |
|
Ve Wong Corp
TW:1203
|
Taiwan | NT$3.14 Billion |
|
Plumas Bancorp
NASDAQ:PLBC
|
USA | $1.98 Billion |
|
ATN International Inc
NASDAQ:ATNI
|
USA | $1.04 Billion |
|
Visco Vision Inc.
TW:6782
|
Taiwan | NT$1.84 Billion |
|
Shanghai Trendzone Decor Grp
SHG:603030
|
China | CN¥1.15 Billion |
|
Beijing InHand Networks Technology Co Ltd
SHG:688080
|
China | CN¥231.99 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Enanta Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ENTA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enanta Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual total liabilities of Enanta Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $216.01 Million | -12.84% |
| 2024-09-30 | $247.84 Million | +0.94% |
| 2023-09-30 | $245.54 Million | +314.37% |
| 2022-09-30 | $59.26 Million | +43.02% |
| 2021-09-30 | $41.43 Million | +17.67% |
| 2020-09-30 | $35.21 Million | +28.80% |
| 2019-09-30 | $27.34 Million | +33.04% |
| 2018-09-30 | $20.55 Million | -17.68% |
| 2017-09-30 | $24.96 Million | +120.10% |
| 2016-09-30 | $11.34 Million | +15.07% |
| 2015-09-30 | $9.86 Million | +45.78% |
| 2014-09-30 | $6.76 Million | +3.94% |
| 2013-09-30 | $6.50 Million | -20.99% |
| 2012-09-30 | $8.23 Million | -94.79% |
| 2011-09-30 | $158.06 Million | -- |
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more